bazlitoran

Bazlitoran is a first-in-class antisense oligonucleotide and investigational drug that acts as an antagonist of endosomal Toll-like receptors (TLRs) 7, 8, and 9. It was originally developed by Idera Pharmaceuticals (now Aceragen) for the treatment of rare hematologic malignancies and autoimmune diseases. Its mechanism involves blocking TLR7/8/9 signaling to reduce inflammatory responses implicated in diseases such as Waldenstrom's macroglobulinemia and diffuse large B cell lymphoma. Bazlitoran has orphan drug status for these indications but development has been suspended or discontinued in several disease areas[1][2][4][7].

Other names

ALL-P-AMBO-2'-DEOXY-P-THIOCYTIDYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-DEOXY-P-THIOADENYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-DEOXY-P-THIOCYTIDYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-O-METHYL-P-THIOGUANYLYL-(3'->5')-2'-O-METHYL-P-THIOURIDYLYL-UNII 2U46M95B5MUNII2U46M95B5MUNII-2U46M95B5MCAS 1378549‑07‑5Bazlitoran sodium